Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;26(12):721-732.
doi: 10.1007/s11883-024-01243-1. Epub 2024 Oct 10.

PCSK9 Monoclonal Antibodies Have Come a Long Way

Sandra Zendjebil  1   2   3 , Philippe Gabriel Steg  4   5   6
Affiliations
Review

PCSK9 Monoclonal Antibodies Have Come a Long Way

Sandra Zendjebil et al. Curr Atheroscler Rep. 2024 Dec.

Abstract

Purpose of the review: This review examines the pivotal role of monoclonal antibodies against PCSK9 in lipid-lowering therapy, emphasizing their biological and clinical impact.

Recent findings: Randomized controlled trials have validated that PCSK9 monoclonal antibodies (Mabs) effectively reduce LDL-c levels by approximately 50%, even when added to maximal statin therapy. They moreover produce a notable 15-20% relative decrease in major cardiovascular events, with a greater reduction among high-risk patients and no evidence for serious adverse effects, assuaging previous concerns. This review highlights the benefits of PCSK9 Mabs in high cardiovascular risk patients. Despite their efficacy and safety, these therapies are hindered by limited access, and require broader integration into clinical practice to optimize therapeutic outcomes.

Keywords: Alirocumab; Bococizumab; Evolocumab; Inclisiran; LDL cholesterol; PCSK9.

PubMed Disclaimer

References

    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144 . - DOI - PubMed - PMC
    1. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–6. https://doi.org/10.1038/ng1161 . - DOI - PubMed
    1. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5. https://doi.org/10.1038/ng1509 . - DOI - PubMed
    1. Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–24. https://doi.org/10.1194/jlr.R026658 . - DOI - PubMed - PMC
    1. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest. 2006;116(11):2995–3005. https://doi.org/10.1172/JCI29383 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources